AFINITOR is contraindicated in patients with hypersensitivity to everolimus, other rapamycin derivatives, or any excipients.
Noninfectious pneumonitis was reported in up to 19% of patients...
When it Comes to Patient Support—We’ve Got It Covered
We know that our patients need prompt access to affordable medication right from the beginning. That’s why the We’ve Got It Covered Program helps patients get started on the therapy you prescribe and then works to help them stay on it. Whatever the insurance coverage challenge, we’re committed to helping make AFINITOR® (everolimus) Tablets accessible to eligible patients.
Bridging the Gap—With a 14-day Supply
The AFINITOR 14-Day Free Trial helps eligible patients start therapy quickly. A 14-day supply is shipped directly to a patient’s home or another convenient location. This one-time trial is available to all patients prescribed AFINITOR for a US Food and Drug Administration (FDA)-approved indication without regard to purchase of AFINITOR or any other product.
Novartis Oncology shares your commitment to helping patients receive the medicines they need. Patient Assistance Now Oncology (PANO) provides access to information and our wide range of resources available to your patients in over 160 languages.
Support for patients includes:
Universal Co-pay Card Program
Patients may be eligible for immediate co-pay savings on their next prescription:
*Limitations apply. See program terms and conditions at www.CoPay.NovartisOncology.com. Offer is not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice.
Terms and Conditions
This offer is valid only for those with commercial insurance. Offer not valid under Medicare, Medicaid, or any other federal or state program. Not valid for cash-paying patients, where product is not covered by patient’s commercial insurance, or where plan reimburses you for entire cost of your prescription drug. Offer is not valid where prohibited by law. Valid only in the United States and Puerto Rico. This program is not health insurance. Offer may not be combined with any other rebate, coupon, or offer. The card is the property of Novartis Pharmaceuticals Corporation and must be returned upon request. Novartis reserves the right to rescind, revoke, or amend the program without notice. Patient certifies responsibility for complying with applicable limitations, if any, of any commercial insurance and reporting receipt of program rewards, if necessary, to any commercial insurer. This offer expires on December 31, 2017. Additional Terms and Conditions may apply.
Encourage your patients to find out if they are eligible to enroll in the Universal Co-pay Program by visiting www.CoPay.NovartisOncology.com or calling 1-877-577-7756.
Patients with commercial insurance are responsible for $0 for a 28-day supply and Novartis pays up to $15,000 per calendar year. If patient reaches the maximum annual cap per calendar year of $15,000, patient will be responsible for the difference. This offer expires on December 31, 2017. Patient questions should be directed to: 1-877-577-7756. When you use this offer, you are certifying that you understand the program rules, regulations, and terms and conditions, and that you will disclose and report the use of this offer as may be required by your insurer. You are not eligible if prescriptions are paid by any federal or state program, or where prohibited by law; and you will otherwise comply with the terms and conditions above.
Abbreviations: CI, confidence interval; HR, hazard ratio; PFS, progression-free survival.
Important Safety Information
AFINITOR is contraindicated in patients with hypersensitivity to everolimus, to other rapamycin derivatives, or to any of the excipients.
Angioedema With Concomitant Use of Angiotensin-Converting Enzyme (ACE) Inhibitors:
Impaired Wound Healing:
Laboratory Tests and Monitoring:
Please see full Prescribing Information.